CONTEXT: Vitamin D deficiency and frailty are common with aging, but the association between these conditions is uncertain. OBJECTIVE: To determine the association between 25-hydroxyvitamin D (25(OH)D) levels and prevalent and incident frailty status among older women. DESIGN: Cross-sectional and longitudinal analyses of a prospective cohort study. SETTING: Four U.S. centers. PARTICIPANTS: 6307 women aged≥69 years. MAIN OUTCOME MEASURES: Frailty status classified as robust, intermediate stage, or frail at baseline; and robust, intermediate stage, frail, or dead (all-cause mortality) at follow-up an average of 4.5 years later. RESULTS: At baseline, there was a U-shaped association between 25(OH)D level and odds of frailty with the lowest risk among women with levels 20.0-29.9 ng/ml (referent group). Compared with this group, the odds of frailty were higher among those with levels<15.0 ng/ml [multivariable odds ratio (MOR) 1.47, 95% confidence interval (CI), 1.19-1.82], those with levels 15.0-19.9 ng/ml (MOR 1.24, 95% CI 0.99-1.54), and those with levels≥30 ng/ml (MOR 1.32, 95% CI 1.06-1.63). Among 4551 nonfrail women at baseline, the odds of frailty/death (vs. robust/intermediate) at follow-up appeared higher among those with levels 15.0-19.9 ng/ml (MOR 1.21, 95% CI 0.99-1.49), but the CI overlapped 1.0. The odds of death (vs. robust/intermediate/frail at follow-up) was higher among those with levels<15.0 ng/ml (MOR 1.40, 95% CI 1.04-1.88) and those with levels 15.0-19.9 ng/ml (MOR 1.30, 95% CI 0.97-1.75), although the latter association did not quite reach significance. CONCLUSION: Lower (<20 ng/ml) and higher (≥30 ng/ml) levels of 25(OH)D among older women were moderately associated with a higher odds of frailty at baseline. Among nonfrail women at baseline, lower levels (<20 ng/ml) were modestly associated with an increased risk of incident frailty or death at follow-up.
CONTEXT: Vitamin Ddeficiency and frailty are common with aging, but the association between these conditions is uncertain. OBJECTIVE: To determine the association between 25-hydroxyvitamin D (25(OH)D) levels and prevalent and incident frailty status among older women. DESIGN: Cross-sectional and longitudinal analyses of a prospective cohort study. SETTING: Four U.S. centers. PARTICIPANTS: 6307 women aged≥69 years. MAIN OUTCOME MEASURES: Frailty status classified as robust, intermediate stage, or frail at baseline; and robust, intermediate stage, frail, or dead (all-cause mortality) at follow-up an average of 4.5 years later. RESULTS: At baseline, there was a U-shaped association between 25(OH)D level and odds of frailty with the lowest risk among women with levels 20.0-29.9 ng/ml (referent group). Compared with this group, the odds of frailty were higher among those with levels<15.0 ng/ml [multivariable odds ratio (MOR) 1.47, 95% confidence interval (CI), 1.19-1.82], those with levels 15.0-19.9 ng/ml (MOR 1.24, 95% CI 0.99-1.54), and those with levels≥30 ng/ml (MOR 1.32, 95% CI 1.06-1.63). Among 4551 nonfrail women at baseline, the odds of frailty/death (vs. robust/intermediate) at follow-up appeared higher among those with levels 15.0-19.9 ng/ml (MOR 1.21, 95% CI 0.99-1.49), but the CI overlapped 1.0. The odds of death (vs. robust/intermediate/frail at follow-up) was higher among those with levels<15.0 ng/ml (MOR 1.40, 95% CI 1.04-1.88) and those with levels 15.0-19.9 ng/ml (MOR 1.30, 95% CI 0.97-1.75), although the latter association did not quite reach significance. CONCLUSION: Lower (<20 ng/ml) and higher (≥30 ng/ml) levels of 25(OH)D among older women were moderately associated with a higher odds of frailty at baseline. Among nonfrail women at baseline, lower levels (<20 ng/ml) were modestly associated with an increased risk of incident frailty or death at follow-up.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Kristine E Ensrud; Li-Yung Lui; Brent C Taylor; John T Schousboe; Meghan G Donaldson; Howard A Fink; Jane A Cauley; Teresa A Hillier; Warren S Browner; Steven R Cummings Journal: Arch Intern Med Date: 2009-12-14
Authors: Edward W Gregg; Jane A Cauley; Katie Stone; Theodore J Thompson; Douglas C Bauer; Steven R Cummings; Kristine E Ensrud Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Peggy M Cawthon; Lynn M Marshall; Yvonne Michael; Thuy-Tien Dam; Kristine E Ensrud; Elizabeth Barrett-Connor; Eric S Orwoll Journal: J Am Geriatr Soc Date: 2007-08 Impact factor: 5.562
Authors: Kristine E Ensrud; Susan K Ewing; Brent C Taylor; Howard A Fink; Katie L Stone; Jane A Cauley; J Kathleen Tracy; Marc C Hochberg; Nicolas Rodondi; Peggy M Cawthon Journal: J Gerontol A Biol Sci Med Sci Date: 2007-07 Impact factor: 6.053
Authors: Michelle Shardell; Gregory E Hicks; Ram R Miller; Stephen Kritchevsky; Daniel Andersen; Stefania Bandinelli; Antonio Cherubini; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2009-01-20 Impact factor: 6.053
Authors: Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka Journal: Rev Endocr Metab Disord Date: 2012-03 Impact factor: 6.514
Authors: Clifford J Rosen; John S Adams; Daniel D Bikle; Dennis M Black; Marie B Demay; JoAnn E Manson; M Hassan Murad; Christopher S Kovacs Journal: Endocr Rev Date: 2012-05-17 Impact factor: 19.871
Authors: M Bonnefoy; G Berrut; B Lesourd; M Ferry; T Gilbert; O Guérin; O Hanon; C Jeandel; E Paillaud; A Raynaud-Simon; G Ruault; Y Rolland Journal: J Nutr Health Aging Date: 2015-03 Impact factor: 4.075
Authors: Erin S LeBlanc; Joanne H Rizzo; Kathryn L Pedula; Kristine E Ensrud; Jane Cauley; Marc Hochberg; Teresa A Hillier Journal: J Womens Health (Larchmt) Date: 2012-06-25 Impact factor: 2.681
Authors: Lisa Langsetmo; Claudie Berger; Nancy Kreiger; Christopher S Kovacs; David A Hanley; Sophie A Jamal; Susan J Whiting; Jacques Genest; Suzanne N Morin; Anthony Hodsman; Jerilynn C Prior; Brian Lentle; Millan S Patel; Jacques P Brown; Tassos Anastasiades; Tanveer Towheed; Robert G Josse; Alexandra Papaioannou; Jonathan D Adachi; William D Leslie; K Shawn Davison; David Goltzman Journal: J Clin Endocrinol Metab Date: 2013-05-23 Impact factor: 5.958